MSD’s Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

Press/Media: Press / Media

PeriodApr 24 2015

Media coverage

20

Media coverage

  • TitleMSD’s Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletReuters
    CountryUnited Kingdom
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletReuters
    CountryUnited Kingdom
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletBloomberg
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletMorningstar.com
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletTMC Net
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletTMC Net
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMSD’s Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletWorld Energy Source
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletWorld Energy Source
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMSD’s Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletEON: Enhanced Online News
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletTamar Securities
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMERCK : Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outlet4 Traders
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletEON: Enhanced Online News
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbas...
    Media name/outletFinwin
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletGadgets TMCnet
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletPharmacy Choice
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletPipelineReview
    CountrySpain
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletPharma Voice
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletFinanzNachrichten.de
    CountryGermany
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date4/24/15
    PersonsEric J Lawitz
  • TitleMerck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range ...
    Media name/outletEIN News
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz